Rivulet Media Inc (fka RIVU)

[Inoviorulez]

It's possible, short sellers could drive it down if FDA questions aren't satisfactory, but considering what Koos did I don't think the FDA will deny it. If you read the press release it says this

"As part of the response to comments, Regen BioPharma provided new data demonstrating efficacy of the HemaXellerate product at accelerating stem cell recovery after chemotherapeutic injury."

So while there is small chance the FDA may want more questions, I feel confident in the fact that Biomatrix added more efficacy data to prove their point. Therefore I am concluding that the FDA should have no problem allowing the dosing to begin.